The LEANORA study: Understanding the pharmacokinetics and pharmacogenomics of ribociclib in Black women
This study examined ribociclib pharmacokinetics and pharmacogenomics in 14 Black women with advanced breast cancer. The LEANORA study (NCT04657679) revealed that the ribociclib exposure and toxicity profile were similar between intermediate/normal and poor CYP3A5 metabolizers.